Aclarion publishes CEO shareholder letter highlighting scan volume growth and advancing clinical program in third quarter 2026
ACON•Aclarion said scan volume grew 85% year over year in the third quarter and 117% in the first nine months of 2026. It reported $14.20 million in cash, said funding extends into the second half of 2027, and expects an initial readout from its 300-patient CLARITY trial by year-end.
1. Growth and trial update
Aclarion published a CEO shareholder letter highlighting its clinical program and scan volume growth. The company said third-quarter scan volume rose 85% year over year and volume for the nine months ended September 30 rose 117%; it reported $14.20 million in cash, said the funds provide runway into the second half of 2027 and support its 300-patient CLARITY trial, and said the trial remains on track for an initial readout by year-end.
